Conversely, in 2012 a Cochrane metaanalysis of 91 controlled studies on ESAs therapy for cancer anemia documented a significantly elevated risk of thrombotic events regardless of the baseline Hb levels (Tonia et al., 2012). This evidence concerns the gene GSTM1 and anemia.